BC Week In Review | Jan 30, 2006
Company News

Novexel management update

Novexel , Romainville, France   Business: Infectious   Hired: Gordon Waldron as CFO, formerly VP and CFO at Synt:em S.A.  ...
BioCentury | Jun 27, 2005
Product Development

Insulin rush

One of the hottest ideas in diabetes today is inhibition of dipeptidyl peptidase IV. The two companies with the most advanced compounds in the field - Merck & Co. Inc. and Novartis AG - presented Phase II...
BC Week In Review | Apr 18, 2005
Clinical News

Syn1001 neurology data

Synt:em S.A. , Nimes, France   Product: Syn1001   Business: Neurology   Molecular target: Undisclosed   Description: Morphine 6 glucoronide ( M6G ) chemically linked to a pep:trans peptide vector   Indication: Treat pain   Endpoint: NA  ...
BC Week In Review | Mar 21, 2005
Company News

Sonus, Synt:em deal

Sonus Pharmaceuticals Inc. (SNUS), Bothell, Wash.   Synt:em S.A. , Nimes, France   Business: Drug delivery, Neurology, Cancer   SNUS terminated its proposed stock acquisition of Synt:em in order to focus on its Tocosol Paclitaxel, which...
BioCentury | Mar 21, 2005
Finance

Ebb & Flow

Phase III Avastin data always seem to be good for an $11 billion pop in Genentech's market cap, and the company is two for two on that front. Such was the case in 2003, when...
BioCentury | Mar 21, 2005
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 3/11 cls Genentech (DNA) Lazard Joel Sendek Price target Buy 19% $52.51 Legg Mason Edward Nash Other Hold WR Hambrecht Jason Kantor Other Buy...
BC Extra | Mar 16, 2005
Company News

Sonus terminates Synt:em acquisition

SNUS terminated its previously proposed stock acquisition of Synt:em (Nimes, France). SNUS said it wants to focus on its Tocosol Paclitaxel, which is expected to start Phase III testing in the third quarter. SNUS ended...
BC Week In Review | Jan 3, 2005
Company News

Sonus, Synt:em deal

Sonus Pharmaceuticals Inc. (SNUS), Bothell, Wash.   Synt:em S.A. , Nimes, France   Business: Drug delivery, Neurology, Cancer   The companies revised the terms of SNUS's proposed acquisition of Synt:em to decrease the total number of...
BioCentury | Nov 15, 2004
Strategy

Sonus reaches an event horizon

Sonus Pharmaceuticals Inc. 's proposed acquisition of Synt:em S.A. is one of a succession of near-term events necessary for SNUS to escape the one-product-company trap. In addition to the acquisition, in the next six months...
BC Week In Review | Nov 8, 2004
Company News

Sonus, Synt:em deal

Sonus Pharmaceuticals Inc. (SNUS), Bothell, Wash.   Synt:em S.A. , Nimes, France   Business: Drug delivery, Neurology, Cancer   SNUS will acquire Synt:em for an initial payment of about $10 million in stock. Synt:em shareholders are...
Items per page:
1 - 10 of 47
BC Week In Review | Jan 30, 2006
Company News

Novexel management update

Novexel , Romainville, France   Business: Infectious   Hired: Gordon Waldron as CFO, formerly VP and CFO at Synt:em S.A.  ...
BioCentury | Jun 27, 2005
Product Development

Insulin rush

One of the hottest ideas in diabetes today is inhibition of dipeptidyl peptidase IV. The two companies with the most advanced compounds in the field - Merck & Co. Inc. and Novartis AG - presented Phase II...
BC Week In Review | Apr 18, 2005
Clinical News

Syn1001 neurology data

Synt:em S.A. , Nimes, France   Product: Syn1001   Business: Neurology   Molecular target: Undisclosed   Description: Morphine 6 glucoronide ( M6G ) chemically linked to a pep:trans peptide vector   Indication: Treat pain   Endpoint: NA  ...
BC Week In Review | Mar 21, 2005
Company News

Sonus, Synt:em deal

Sonus Pharmaceuticals Inc. (SNUS), Bothell, Wash.   Synt:em S.A. , Nimes, France   Business: Drug delivery, Neurology, Cancer   SNUS terminated its proposed stock acquisition of Synt:em in order to focus on its Tocosol Paclitaxel, which...
BioCentury | Mar 21, 2005
Finance

Ebb & Flow

Phase III Avastin data always seem to be good for an $11 billion pop in Genentech's market cap, and the company is two for two on that front. Such was the case in 2003, when...
BioCentury | Mar 21, 2005
Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 3/11 cls Genentech (DNA) Lazard Joel Sendek Price target Buy 19% $52.51 Legg Mason Edward Nash Other Hold WR Hambrecht Jason Kantor Other Buy...
BC Extra | Mar 16, 2005
Company News

Sonus terminates Synt:em acquisition

SNUS terminated its previously proposed stock acquisition of Synt:em (Nimes, France). SNUS said it wants to focus on its Tocosol Paclitaxel, which is expected to start Phase III testing in the third quarter. SNUS ended...
BC Week In Review | Jan 3, 2005
Company News

Sonus, Synt:em deal

Sonus Pharmaceuticals Inc. (SNUS), Bothell, Wash.   Synt:em S.A. , Nimes, France   Business: Drug delivery, Neurology, Cancer   The companies revised the terms of SNUS's proposed acquisition of Synt:em to decrease the total number of...
BioCentury | Nov 15, 2004
Strategy

Sonus reaches an event horizon

Sonus Pharmaceuticals Inc. 's proposed acquisition of Synt:em S.A. is one of a succession of near-term events necessary for SNUS to escape the one-product-company trap. In addition to the acquisition, in the next six months...
BC Week In Review | Nov 8, 2004
Company News

Sonus, Synt:em deal

Sonus Pharmaceuticals Inc. (SNUS), Bothell, Wash.   Synt:em S.A. , Nimes, France   Business: Drug delivery, Neurology, Cancer   SNUS will acquire Synt:em for an initial payment of about $10 million in stock. Synt:em shareholders are...
Items per page:
1 - 10 of 47